NCT05624879 Accelerated Resolution Therapy for Early Maladaptive Grief
| NCT ID | NCT05624879 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Grief |
| Study Type | INTERVENTIONAL |
| Enrollment | 440 participants |
| Start Date | 2023-11-17 |
| Primary Completion | 2028-03-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 440 participants in total. It began in 2023-11-17 with a primary completion date of 2028-03-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.
Eligibility Criteria
Inclusion Criteria: * Primary caregiver of immediate family member who has a life expectancy of less than 12 months * Score of 30 or higher on the PG-12-R, indicating clinically significant pre-loss grief * Denial of suicidal ideation or intent, with no evidence of psychotic behavior. Exclusion Criteria: * Since becoming a family caregiver (FCG), they have engaged in another trauma based psychotherapeutic regimen (EMDR, prolonged exposure therapy, trauma focused cognitive behavioral therapy) that could influence response to accelerated resolution therapy (ART). * Self-reported or clinically assessed major psychiatric disorder (e.g., bipolar disorder, schizophrenia). * Score of \> 2 on the adapted CAGE questionnaire indicating alcohol /drug dependence. * Cognitive impairment (SPMSQ \> 4 errors).
Contact & Investigator
Cindy Tofthagen, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05624879 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Grief. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05624879 currently recruiting?
Yes, NCT05624879 is actively recruiting participants. Contact the research team at Sheffield.Katharine@mayo.edu for enrollment information.
Where is the NCT05624879 trial being conducted?
This trial is being conducted at Phoenix, United States, Clearwater, United States, Jacksonville, United States, Rochester, United States.
Who is sponsoring the NCT05624879 clinical trial?
NCT05624879 is sponsored by Mayo Clinic. The principal investigator is Cindy Tofthagen, PhD at Mayo Clinic. The trial plans to enroll 440 participants.